^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P1 agonist

    Related drugs:
    8d
    A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1)
    |
    TP53 mutation • SF3B1 mutation • Chr del(5q)
    |
    cytarabine • azacitidine • cladribine • melphalan • busulfan
    26d
    OCR_CLAD: Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients (clinicaltrials.gov)
    P=N/A, N=70, Active, not recruiting, Ente Ospedaliero Cantonale, Bellinzona | Recruiting --> Active, not recruiting
    Enrollment closed
    28d
    Aggressive Systemic Mastocytosis Presenting as Diffuse Osteoblastic Bone Disease: A Diagnostic Pitfall Mimicking Metastatic Cancer. (PubMed, Eur J Case Rep Intern Med)
    Aggressive mastocytosis can rarely present with diffuse osteoblastic bone lesions mimicking metastatic disease.Elevated serum tryptase and histopathological confirmation are essential for diagnosis, even when KIT mutations are absent.Early recognition prevents unnecessary oncologic investigations and allows timely initiation of cytoreductive therapy.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD68 (CD68 Molecule)
    |
    KIT mutation
    |
    cladribine
    29d
    A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    1m
    A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Dec 2025 --> Dec 2027
    Trial initiation date
    |
    RAS mutation
    |
    cytarabine
    2ms
    Clad'Action: Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=77, Completed, University Hospital, Rouen | Recruiting --> Completed
    Trial completion
    |
    IFNB1 (Interferon Beta 1)
    2ms
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    3ms
    Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Jakafi (ruxolitinib)
    6ms
    Cladribine Venetoclax in Monocytic AML (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Colorado, Denver | N=40 --> 20
    Enrollment change
    |
    Venclexta (venetoclax)
    7ms
    ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=204, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting
    Enrollment closed • HEOR
    7ms
    DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
    P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial completion date: Sep 2030 --> Jul 2027
    Trial completion date
    |
    Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)